Navigation Links
Independent Publication Confirms Growing Therapeutic Challenge of,T315I Mutation in Patients with CML, Notes ChemGenex

t from second-line treatment with dasatinib".

Data from this publication support ChemGenex’s two-pronged phase 2/3 clinical approach for Ceflatonin, targeting Gleevec-resistant CML patients who harbour the T315I mutation, as well as CML patients who have failed two tyrosine kinase inhibitors (usually Gleevec and Sprycel).

Gleevec®/Glivec® is a registered trademark of Novartis AG.

Sprycel® is a registered trademark of the Bristol-Myers Squibb Company.

Ceflatonin® is a registered trademark of ChemGenex Pharmaceuticals Limited.

About ChemGenex Pharmaceuticals Limited (www.chemgenex.com)

ChemGenex Pharmaceuticals is a pharmaceutical development company dedicated to improving the lives of patients by developing therapeutics in the areas of oncology, diabetes, obesity, and depression. ChemGenex harnesses the power of genomics for target discovery and validation, and in clinical trials to develop more individualized therapeutic outcomes. ChemGenex’s lead compound, Ceflatonin®, is currently in phase 2/3 clinical trials for chronic myeloid leukemia (CML) and Quinamed® is in phase 2 clinical development for prostate, breast and ovarian cancers. The company has a significant portfolio of anti-cancer, diabetes, obesity and depression programs, several of which have been partnered with international pharmaceutical companies. ChemGenex currently trades on the Australian Stock Exchange under the symbol "CXS" and on NASDAQ under the symbol "CXSP".

Contacts

Dr. Greg Collier (CEO and Managing Director) Australia +61 3 5227 2752

USA +1 650 474 9800 ext 103

Dr. Dennis Brown (President and Director) USA +1 650 474 9800 ext 108

Australia +61 3 5227 2703

Safe Harbor Statement

Certain statements made he
'"/>




Page: 1 2 3

Related medicine technology :

1. Molecular Target of Bradmers Neuradiab Further Validated by Independent Findings
2. Independent Publication Confirms Growing Therapeutic Challenge of T315I Mutation in Patients with CML, Notes ChemGenex
3. Study Continues to Show Patients With Myelodysplastic Syndromes Treated With Revlimid are Living Longer and Remaining Transfusion Independent
4. Independent publication supports the profile of CeNeS phase II compound, CNS 5161
5. Data Presented at AACR Meeting Shows Bavituximab Equivalent Plus Docetaxel Reduces Growth of Both Hormone-Dependent and Hormone-Independent Prostate Cancer by Up to 94 Percent in Preclinical Studies
6. Response Genetics Announces Publication of a Phase III Clinical Trial Demonstrating That Low Levels of ERCC-1 Help to Predict Likelihood of Response to Cisplatin-Based Therapy in Lung Cancer
7. DOR BioPharma Announces Publication Describing Results of Its Multivalent Botulinum Toxin Vaccine BT-VACC
8. Publication Confirms that EpCAM, the Target for Two of Micromets Product Candidates, Is Overexpressed on Cancer Stem Cells of Certain Cancers
9. Publication on Pixantrone Preclinical Studies Demonstrates Reduced Cardiotoxicity Compared to Equiactive Doses of Doxorubicin and Mitoxantrone
10. Neurologix Announces Publication of Landmark Gene Therapy Study Demonstrating Safety and Statistically Significant Improvement in Patients With Advanced Parkinsons Disease
11. Nuvelo Announces Publication of Phase 2 rNAPc2 Study Results in Journal of American College of Cardiology
Post Your Comments:
(Date:5/22/2013)... --  Accuray Incorporated (Nasdaq: ARAY ), ... at the 2013 Jefferies Global Healthcare Conference in ... 2013 at 1:30 p.m. EDT/10:30 a.m. PDT. ... online from the Investor Relations page of the Company,s ... of the presentation will begin approximately one hour after ...
(Date:5/22/2013)... , May 22, 2013 JenaValve Technology, Inc., a ... implantation (TAVI) systems for the treatment of aortic valve disease, ... enaValve Eval U ation of Long Term P erformance ... E vere Ao R tic Stenosis (JUPITER) Registry at EuroPCR ... registry to evaluate five-year long term safety and effectiveness of ...
(Date:5/22/2013)... 22, 2013  The Lupus Research Institute (LRI) today ... new treatments for lupus nephritis, a serious kidney complication ... The conference launched a new international alliance of researchers ... Network (LNTN). More than 50 of the ... together to focus on two critical questions: 1) Which ...
Breaking Medicine Technology:First Results Of The JUPITER Registry On Long Term Performance And Safety Of The Transapical JenaValve TAVI System 2First Results Of The JUPITER Registry On Long Term Performance And Safety Of The Transapical JenaValve TAVI System 3First Results Of The JUPITER Registry On Long Term Performance And Safety Of The Transapical JenaValve TAVI System 4Lupus Research Institute Hosts First International Conference to Advance New Treatments for Lupus Nephritis 2
... PORTLAND, Ore., May 13 Dried blood spots ... collection and transport,for blood tests. In an article ... Science and Technology (2008; 2(2):242-3), Ramakrishnan Lakshmy,PhD, explains ... a "powerful tool", for,mass disease screening programs, especially ...
... to replace the,faulty CLN2 gene, which causes a neurodegenerative ... to slow significantly the rate of neurologic,decline in treated ... in the May 2008 issue (Vol. 19 No. 5) ... Ann Liebert, Inc. The paper is,available free online at ...
Cached Medicine Technology:Blood Spot Technology at ZRT Highlighted in March Issue of Journal of Diabetes Science & Technology - A Convenient Alternative to Serum Testing for Health Screening 2Gene Therapy Slows Progression of Fatal Neurodegenerative Disease in Children 2
(Date:5/23/2013)... (PRWEB) May 23, 2013 911 Signal USA ... expo will begin on May 22 and run through May ... and information about the company's emergency vehicle lights ... new 2013 Dodge Charger at the expo. , The Charger ... on the market and can be seen by visiting 911 ...
(Date:5/22/2013)... 2013 Most women dread cellulite and ... factors, including estrogen being a factor in the formation ... deposits stored and smashed together which create that dimpling ... take a multi-pronged action," says Kathy Heshelow, founder of ... products like Cellulite Whisperer ® that work to ...
(Date:5/22/2013)... Catalyst Exhibits, Inc., an award-winning global ... its website that allows visitors to view a ... immersive, 360-degree, interactive experience. , The new viewing ... virtually experience the exhibit design Catalyst created for St. ... Users have the ability to interact with the hi-resolution ...
(Date:5/22/2013)... San Francisco, CA (PRWEB) May 22, 2013 ... funerals costing $6,500 or more on average, a funeral concierge ... a funeral, among other benefits. Funeral Financials ... With the average household income in the U.S. ... recession according to Sentier Research, the average funeral costs 12.6% ...
(Date:5/22/2013)... MD (PRWEB) May 22, 2013 On a ... Lisa, spent a few hours watching “The Bourne Legacy” at ... While this may seem like a typical activity to many ... This little stretch of respite from their everyday reality has ... Seals Serving DC | MD | VA. , Life changed ...
Breaking Medicine News(10 mins):Health News:911 Signal USA Attends the 2013 Southwest Police Fleet Expo 2Health News:Get Cellulite Under Control Now with Cellulite Whisperer® Products Introduced by Sublime Beauty® 2Health News:Catalyst Exhibits Debuts 360 Degree Virtual Tour of St. Jude Medical Trade Show Booth 2Health News:Funeral Financials Announces Their Top 3 Reasons to Hire a Funeral Concierge 2Health News:Funeral Financials Announces Their Top 3 Reasons to Hire a Funeral Concierge 3Health News:Military Family Finds Respite with Easter Seals 2Health News:Military Family Finds Respite with Easter Seals 3
... Center have found that the reflux and swallowing problems ... and other neurological impairments, may be caused by a ... finding leaves researchers to wonder if these patients truly ... , In a study published in this quarter,s ...
... some cases, parents encourage the habit, U.S. survey shows , , ... American adolescents are getting early and regular exposure to violent ... almost 13 percent of the nation,s estimated 22 million children ... graphic depictions of violence in film, whether in theaters, on ...
... WellPoint, Inc. (NYSE: WLP ) today,announced the ... its Senior,Business and Consumer Business marketing, effective immediately., ... responsible for leading WellPoint,s,Medicare business division and Consumer ... benefit from the unique knowledge of,Medicare and marketing ...
... for HIV do not increase the risk for coronary atherosclerosis, ... study led by the University of Pittsburgh Graduate School of ... of the journal AIDS and available online today. ... with HIV some protection against atherosclerosis hardening of the ...
... in 2003, when seven people who called themselves ... Team Sarcoma Initiative has become an international movement.,More ... Initiative, surpassing the 3,400 who participated last year. ... advocacy groups and medical centers seeking to raise ...
... appropriate patients ... to help them reach ... blood pressure goals, - Single-pill combinations offer effective, convenient medications which ... treatment goals faster, - Diovan HCT and Exforge approvals may benefit patients who are ...
Cached Medicine News:Health News:Researchers find differences in swallowing mechanism of Rett syndrome patients 2Health News:Many Kids Under 15 Watch Violent Movies 2Health News:Many Kids Under 15 Watch Violent Movies 3Health News:WellPoint Appoints Krista A. Bowers as President of Senior Business 2Health News:Long-term HIV treatment may reduce risk for atherosclerosis 2Health News:8,000 People Join the Team Sarcoma Initiative to Fight a Rare Cancer 2Health News:8,000 People Join the Team Sarcoma Initiative to Fight a Rare Cancer 3Health News:8,000 People Join the Team Sarcoma Initiative to Fight a Rare Cancer 4Health News:8,000 People Join the Team Sarcoma Initiative to Fight a Rare Cancer 5Health News:Single-Pill Combinations Diovan HCT and Exforge Approved in US as First-Line Treatments for High Blood Pressure 2Health News:Single-Pill Combinations Diovan HCT and Exforge Approved in US as First-Line Treatments for High Blood Pressure 3Health News:Single-Pill Combinations Diovan HCT and Exforge Approved in US as First-Line Treatments for High Blood Pressure 4Health News:Single-Pill Combinations Diovan HCT and Exforge Approved in US as First-Line Treatments for High Blood Pressure 5Health News:Single-Pill Combinations Diovan HCT and Exforge Approved in US as First-Line Treatments for High Blood Pressure 6Health News:Single-Pill Combinations Diovan HCT and Exforge Approved in US as First-Line Treatments for High Blood Pressure 7
It is designed for rigid skeletal fixation. These pins are constructed of stainless steel and can be removed for sterilization and reuse....
... is designed for rigid skeletal ... greater freedom in positioning the ... skeletal fixation is designed for ... sitting positions. Craniotomies can be ...
Endoscopes...
... borescopes are rigid endoscopes for general applications and ... The diameters of borescopes, i.e. rigid endoscopes, range ... directions from 0 up to a 120 retrospection, ... and wide angle view. Endoscopes with working lengths ...
Medicine Products: